博瑞医药：BGM1812 注射液获批开展超重或肥胖的临床试验

Group 1 - The core point of the article is that Borui Pharmaceutical (688166) has received approval from the National Medical Products Administration for clinical trials of its BGM1812 injection aimed at treating overweight or obesity [1] Group 2 - Borui Pharmaceutical's wholly-owned subsidiary, Borui Medicine, is responsible for the clinical trial of BGM1812 injection [1] - The approval signifies a step forward in the company's efforts to develop treatments for obesity, which is a growing health concern [1]